



Advanced Enzyme Technologies Limited





Disclaimer

This information may contain certain forward-looking statements/details in the current scenario, which is extremely dynamic and increasingly fraught with risks and uncertainties. Actual results, performances, achievements or sequence of events may be materially different from the views expressed herein. Investors/shareholders/public are hence cautioned not to place undue reliance on these statements/details, and are advised to conduct their own investigation and analysis of the information contained or referred to in this section before taking any action with regard to their own specific objectives. Further, the discussion following here in reflects the perceptions on major issues as on date and the opinions expressed here are subject to change without notice. The Company undertakes no obligation to publicly update or revise any of the opinions or forward-looking statements expressed in this section, consequent to new information, future events or otherwise.



Company Overview

What are enzymes?

Enzymes are natural protein molecules that act as catalysts within living cells, produced by all living organisms. Function as specialized catalysts and accelerate the pace of biochemical reactions.

Advanced uses enzymes to replace chemicals in, and improve efficiency of, a wide variety of industrial processes for its customers.



Advanced Enzymes is a research driven company with global leadership in the manufacturing of enzymes and probiotics. We are committed to providing eco-safe solutions to a wide variety of industries like human health care and nutrition, animal nutrition, baking, fruit & vegetable processing, brewing & malting, grain processing, protein modification, dairy processing, speciality applications, textile processing and others. Our aim is to replace traditionally used chemicals with eco-friendly enzymatic solutions.

What are Probiotics?

Probiotics are live microorganisms, when administered in sufficient amount, confer health benefits to human and animals. Probiotics have now become an integral part of several therapies for the digestive disorders and newer applications for treatment of several other diseases are being developed. Probiotics act by fighting with the disease causing microorganisms and by secreting beneficial metabolites in the human/animal system.

Advanced Enzymes has developed and upscaled technologies for the production and application of several important probiotics.

Mission




It is our mission to see that every human being is able to take advantage of the power of enzymes for well-being and leading a healthy life!

Vision



Our vision at Advanced Enzymes is to become the largest, enzyme-based, value provider to consumers and processors globally!



Advanced Enzyme Technologies Limited – A Rising Global Star



Manufacturing Units – 7


India - 5 USA - 2



R&D Units – 6


India – 4 | USA – 1 | Germany – 1

REVENUE (₹ mn)




FY 16 FY 20

EBIDTA (₹ mn)



FY 16 FY 20

PAT (₹ mn)



FY 16 FY 20



Indian enzyme company



Highest market share in India



Listed integrated enzyme player globally



68+

Enzymes & Probiotics



400+

Proprietary Products



700+

Customers Worldwide



45+

Countries Worldwide Presence



550+

Employees



7

Registered Patents



11

Food Enzyme Dossiers filed with EFSA



2*

GRAS Dossier evaluated by US FDA



420

m³ Fermentation Capacity




25+

Years of Fermentation Experience




Note: Facts & Figures as on 31st March 2020

*1 GRAS Dossier under evaluation with US FDA

Note: 2015: as per IGAAP | 2019: as per IndAs






Results Summary – Q2FY21 (Consolidated) Y-o-Y



Revenue Breakup ₹ in Million


*YoY Growth





Note: 1. On Consolidated Basis
2. PAT is before minority

3. Product categorywise revenue does not include other operating income and Ind AS adjustments

4. Ind AS adjustments are carried out on account of commission and discount.



Revenue Split – Q2FY21 vs. Q2FY20




Note: 1. On Consolidated Basis




2. EBIDTA is including other income

3. Segment-wise revenue does not include other operating income

4. Ind AS adjustments are carried out on account of commission and discount.






Results Summary – H1FY21 (Consolidated) Y-o-Y



Revenue Breakup ₹ in Million


*YoY Growth





Note: 1. On Consolidated Basis
2. PAT is before minority

3. Product categorywise revenue does not include other operating income and Ind AS adjustments

4. Ind AS adjustments are carried out on account of commission and discount.



Revenue Split – H1FY21 vs. H1FY20




Note: 1. On Consolidated Basis

2. EBIDTA is including other income

3. Segment-wise revenue does not include other operating income

7. Ind AS adjustments are carried out on account of commission and discount.




Profit & Loss (Consolidated) – Q1FY21 & H1FY21



₹ in Million except per share data


Particulars	Q2FY21 Unaudited	Q1FY21 Unaudited	Q2FY20 Unaudited	Y-o-Y (%)	H1FY21 Unaudited	H1FY20 Unaudited	Y-o-Y (%)
Income from Operations	1,204	1,105	1,114	8%	2,309	2,218	4%
Expenses	687	654	706	(3%)	1,342	1,338	0%
Profit from Operations before Other Income, Finance Costs and Exceptional Item	517	451	408	27%	967	880	10%
Other Income	6	52	15	(60%)	58	26	123%
Profit from ordinary activities before Finance Costs and Exceptional Item	523	503	423	24%	1,025	906	13%
Finance costs	4	5	7	(43%)	8	15	(47%)
Profit from ordinary activities before exceptional item and tax	519	498	416	25%	1,017	891	14%
Profit from ordinary activities before tax	519	498	416	25%	1,017	891	14%
Tax	133	150	98	36%	283	233	21%
Net Profit for the period	386	348	318	21%	734	658	12%
Earnings Per Share	3.33	3.13	2.99		6.40	5.76	






Balance Sheet (Consolidated) – H1FY21

₹ in Million

Particulars	H1FY21 Unaudited	H1FY20 Audited
Assets		
Property, plant and equipment	2,017	1,706
Capital work-in-progress	138	157
Intangible assets	577	594
Goodwill	2,899	2,764
Other non-current assets	170	185
Current assets	4,452	3,396
Assets held for sale	48	48
Total Assets	10,301	8,850
Equity And Liabilities		
Equity share capital	223	223
Other equity	8,743	7,215
Non-controlling interest	291	267
Non-current liabilities	432	460
Current liabilities	557	630
Liabilities classified as held for sale	55	55
Total – Equity and Liabilities	10,301	8,850






Results Summary – FY20



Revenue Breakup ₹ in Million


*YoY Growth





Note: 1. On Consolidated Basis
2. PAT is before minority

3. Segment-wise revenue does not include other operating income and Ind AS adjustments

4. Ind AS adjustments are carried out on account of commission and discount.




Revenue Split – FY20



Note: 1. On Consolidated Basis
2. PAT is before minority

3. Segment-wise revenue does not include other operating income and Ind AS adjustments


4. Ind AS adjustments are carried out on account of commission and discount.



Profit & Loss (Consolidated) – FY20

₹ in Million except per share data


Particulars	FY20 Audited	FY19 Audited	Y-o-Y (%)
Income from Operations	4,440	4,196	6%
Expenses	2,675	2,587	3%
Profit from Operations before Other Income, Finance Costs and Exceptional Item	1,765	1,609	10%
Other Income	57	50	12%
Profit from ordinary activities before Finance Costs and Exceptional Item	1,822	1,659	10%
Finance costs	30	39	(23%)
Profit from ordinary activities before exceptional item and tax	1,792	1,620	11%
Profit from ordinary activities before tax	1,792	1,620	11%
Tax	461	461	0%
Net Profit for the period	1,330	1,159	15%
Earnings Per Share	11.58	9.95	



Balance Sheet (Consolidated) – FY20


₹ in Million

Particulars	FY20 Audited	FY19 Audited
Assets		
Property, plant and equipment	2,042	1,618
Capital work-in-progress	101	105
Intangible assets	646	622
Goodwill	2,941	2,715
Other non-current assets	195	183
Current assets	3,813	2,820
Assets held for sale	48	48
Total Assets	9,786	8,111
Equity And Liabilities		
Equity share capital	223	223
Other equity	8,173	6,565
Non-controlling interest	278	260
Non-current liabilities	461	358
Current liabilities	596	651
Liabilities classified as held for sale	55	54
Total – Equity and Liabilities	9,786	8,111




Strong Financial Performance – FY20


₹ in Million




CAGR=10.87%



CAGR=9.84%



CAGR=10.95%




CAGR=14.72%





Note: As per IGAAP | FY17, FY18, FY19 – as per IndAs

All numbers are on Consolidated basis

ROE = Profit after tax / Average shareholder equity; RoCE = (Net Profit before Tax , Exceptional and extraordinary items + Finance cost) / Average (Net debt + Network)



Strong Financial Performance – FY20




Note: As per IGAAP | FY17, FY18 & FY19 – as per IndAs

All numbers are on Consolidated basis

Net working capital days = $\frac{(\text{Trade receivables} + \text{inventories} - \text{Trade payables})}{\text{Revenue from operations}} \times 365$

Net Debt = Long term debt + short term debt + current maturities of long term debt – Cash & Cash Equivalent



Shareholder Information

Stock Data (As on 11th November 2020)

Market Capitalization (₹)	34,307 mn
Shares Outstanding	111.67 mn
Free Float	4.55 mn
Symbol (NSE/ BSE)	ADVENZYMES / 540025


Top 5 Institutional Holders (As on 06th November 2020)

Institutions	OS (%)
ORBIMED ASIA III MAURITIUS	12.09
HDFC AMC	5.70
NALANDA INDIA EQUITY FUND	4.75
OLD WELL EMERGING MARKETS	0.51
UTI – HEALTHCARE FUND	0.40

Stock Chart (As on 11th November 2020)



Source: BSE, NSE, Thomson Reuters



Note: Data mentioned in above chart is as on 30th September 2020



Thank You

Advanced Enzyme Technologies Limited

Address: 5th Floor, 'A' wing, Sun Magnetica LIC Service Road, Louiswadi, Thane (W) 400 604, India

Tel: +91-22-4170 3200

Web: www.advancedenzymes.com

Fax: + 91-22-25835159

